Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib vs chlorambucil in treatment-naive CLL/SLL patients aged 65 or older
2012-003967-23Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell prolymphocytic leukemia (B-PLL) (2 arms), sponsored by Pharmacyclics. Primary endpoint: Progression-free survival. Started Nov 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on 2012-003967-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003967-23.